Navigation Links
Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
Date:6/21/2013

SAN DIEGO and IRVINE, Calif., June 21, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq™) and IG-004 (TOCOSOL® paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine (CLINAM) and the European Technology Platform on Nanomedicine (ETPN) in Basel, Switzerland on June 23 - 26. Sorrento has the right to acquire IGDRASOL pursuant to a previously-announced option agreement, entered into in March 2013.

IGDRASOL'S data mining of the clinical data for both IG-001 and IG-004 has generated exciting insights into the field of nanomedicine, which will be presented at the joint meeting. These findings are highly relevant to the theme of this year's conference, namely "Nanomedicine & Targeted Medicine – the paradigm of precise, highly effective and innocuous medicine for the benefit of patients and mankind".

IG-001 (Cynviloq™) is a next-generation, branded, micellar diblock copolymeric paclitaxel formulation currently approved and marketed in several countries as Genexol-PM®. It has completed Phase 1 or 2 trials in metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and bladder cancer in the U.S. and/or ex-U.S. IGDRASOL is preparing for an "End of Phase 2" meeting scheduled with the U.S. Food & Drug Administration (FDA) in July 2013, regarding the clinical development of Cynviloq™. As an injectable nanoparticle formulation of paclitaxel, Cynviloq™ may be eligible for approval through the FDA's 505(b)(2) bioequivalence regulatory pathway versus albumin-bound paclitaxel (nab-paclitaxel; Abraxane®) in its currently approved MBC and NSCLC ind
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
2. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
3. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
6. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
7. Sorrento Therapeutics Awarded Third Phase I STTR Grant
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
10. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
11. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)...  Alere Inc. (NYSE: ALR ), a ... Juliet Cunningham as Vice President, Investor Relations. In ... driving communications with the investment community. "As ... to increase shareholder value, it is critical that we ... Chief Executive Officer. "We are delighted that Juliet ...
(Date:11/21/2014)... SARASOTA, Fla. , Nov. 21, 2014   ... ) announced that the Company is scheduled to present ... San Francisco, CA on January 12-14, ... PhD, Chairman and CEO of Rock Creek Pharmaceuticals, will ... small molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. ...
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
Breaking Medicine Technology:Alere Appoints Juliet Cunningham to Lead Investor Relations 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
(Date:11/22/2014)... BambooFlooringChina.com is a famous brand in the bamboo ... collection of bamboo mats ; the new models are ... , According to the sales manager of BambooFlooringChina.com, Bamboo ... highly renewable resource. Their bamboo mats are 100% made from ... from natural bamboo with caramel bamboo strips. , ...
(Date:11/22/2014)... November 22, 2014 In order to provide ... promotion of cocktail party dresses. The business knows that a ... social occasions. , Now, the party dresses supplier’s ... 70% off. As the leading company in fashion industry, LunaDress ... outfit for every customer. So it always raises the professional ...
(Date:11/22/2014)... SATURDAY, Nov. 22, 2014 (HealthDay News) -- The wide ... can pose a threat for people with food allergies, ... there are so many types of food allergies that ... over the holidays," Dr. Guha Krishnaswamy, director of allergy ... said in a hospital news release. "If you ...
(Date:11/22/2014)... Recently, UWDress.com is gratified to introduce its new collection ... the company has also offered an attracting discount on ... supplier of wedding dresses, UWDress.com is good at manufacturing ... guest gowns are provided over 20 colors, which have ... is famous for high quality. Therefore, its sales increased ...
(Date:11/22/2014)... Developers and plugin specialist of Final Cut Pro ... Model bringing the impossible to FCPX from Pixel ... obj files to FCPX enabling 3d Model editing,” said Christina ... professional and armature, FCPX 3D Model is a definite game ... Cut Pro X users to upload and control 3D objects ...
Breaking Medicine News(10 mins):Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:Pixel Film Studios released FCPX 3D Model plugin Exclusively for Final Cut Pro X 2
... ... and navigation enhancement XML API. , ... (PRWEB) May 27, 2010 -- Smartlogic has released a ... websites or in enterprise information management systems, using Semaphore,s search and navigation enhancement XML ...
... Helicobacter pylori , which lives in the human stomach ... like a corkscrew, or helix. For years researchers have hypothesized ... survive and thrive within the stomach,s acid-drenched environment, ... the first time, researchers at Fred Hutchinson Cancer Research Center ...
... Schrader had it all: steady job, a wife, and two ... morethat is, more children. Taking steps to keep his nuclear ... was back on the golf course the next afternoon. ... that followed Schrader would ultimately revisit the issue of having ...
... mood of those with sensitivities worsened when exposed to ... season may not mean just the inevitable coughing, sneezing ... , Researchers reported that finding at the American Psychiatric ... "Depression is a very common disorder and allergies are ...
... , ... announced that they have now added 7,000 stores in under five months of operation. The ... 100-200 new comments per day and 500 votes per day, making it one of the ... ...
... tying genes to common tumors may be invalid, researchers ... sample sizes may undercut the reliability of recent genome ... a Greek-American analysis cautions. , The observation is the ... harnessed technological innovations in so-called "whole genome sequencing" to ...
Cached Medicine News:Health News:Smartlogic Demonstrates Improved User Search, Find and Navigation with Semaphore Open Semantic Platform 2Health News:Shape matters: The corkscrew twist of H. pylori enables it to 'set up shop' in the stomach 2Health News:Shape matters: The corkscrew twist of H. pylori enables it to 'set up shop' in the stomach 3Health News:Robotic-assisted vasectomy reversal offers greater chance of fatherhood 2Health News:Allergies Might Trigger Depression 2Health News:Coupon Site TrimBack.com Adds 7000th Online Store 2Health News:Genes' Link to Certain Cancers Questioned 2
Female Mini-VEST Seamless, Front Closure...
Male Support Brief...
For Lipoplasty or surgery of abdomen, flanks and midriff...
Select Support Brief...
Medicine Products: